Ad is loading...
DGECX
Price
$19.50
Change
-$0.18 (-0.91%)
Updated
Nov 15 closing price
RNWFX
Price
$80.56
Change
-$0.79 (-0.97%)
Updated
Nov 15 closing price
Ad is loading...

DGECX vs RNWFX

Header iconDGECX vs RNWFX Comparison
Open Charts DGECX vs RNWFXBanner chart's image
BNY Mellon Global Emerging Mkts - C
Price$19.50
Change-$0.18 (-0.91%)
VolumeN/A
CapitalizationN/A
American Funds New World R5
Price$80.56
Change-$0.79 (-0.97%)
VolumeN/A
CapitalizationN/A
DGECX vs RNWFX Comparison Chart
Loading...
View a ticker or compare two or three
VS
DGECX vs. RNWFX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DGECX is a Buy and RNWFX is a Buy.

FUNDAMENTALS
Fundamentals
RNWFX has more cash in the bank: 60.9B vs. DGECX (395M). RNWFX pays higher dividends than DGECX: RNWFX (1.51) vs DGECX (0.00). DGECX was incepted earlier than RNWFX: DGECX (11 years) vs RNWFX (23 years). DGECX is a more actively managed with annual turnover of: 44.72 vs. RNWFX (32.00). RNWFX has a lower initial minimum investment than DGECX: RNWFX (250) vs DGECX (1000). RNWFX annual gain was more profitable for investors over the last year : 11.54 vs. DGECX (7.79). DGECX return over 5 years is better than : 25.45 vs. RNWFX (17.17).
DGECXRNWFXDGECX / RNWFX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence11 years23 years-
Gain YTD3.0667.09943%
Front LoadN/AN/A-
Min. Initial Investment1000250400%
Min. Initial Investment IRAN/AN/A-
Net Assets395M60.9B1%
Annual Yield % from dividends0.001.51-
Returns for 1 year7.7911.5468%
Returns for 3 years-27.94-14.55192%
Returns for 5 years25.4517.17148%
Returns for 10 years32.7641.0080%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VRNA35.660.29
+0.82%
Verona Pharma plc
BURL268.94-0.65
-0.24%
Burlington Stores
RCMT22.25-0.38
-1.68%
RCM Technologies
SNTI2.15-0.18
-7.73%
Senti Biosciences Inc.
CATX7.88-1.04
-11.66%
Perspective Therapeutics